contraindications of glp 1 agonist for glp-1 Consensus Recommendations on GLP-1 RA Use in the Management Type 2 Diabetes Mellitus: South Asian Task Force Frontiers | Exploring the multifaceted

doi: 10.1172/JCI105685 5 McintyreNHoldsworthCDTurnerDS

Longer life expectancy with less risk of premature death from heart disease, stroke, diabetes, and other obesity-related conditions

Additionally, a well-established infrastructure for injectable delivery in hospitals and clinics ensures continued dominance

Studies have shown that GLP-1 agonists can trigger effects in the brain, the heart, the liver, the pancreas, the stomach, and the musclesmeaning that they could have implications for conditions other than type 2 diabetes and obesity, such as heart disease, kidney disease, liver disease, and even neurological conditions such as Alzheimer's disease

SGLT2 includes Jardiance, Farxiga, and Invokana Source: IQVIA Market Share Library